Evidence map›Paper›PMID 30516928›Full record

ArticleInternational braz j urol : official journal of the Brazilian Society of Urology

Prognostic significance of body mass index in patients with localized renal cell carcinoma.

Chengtao Wang, Zebin Chen, Jun Dong, Bixiu Wen, Yong Fang

Abstract read
In one paragraph

Article in International braz j urol : official journal of the Brazilian Society of Urology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Chengtao WangDepartment of Radiation Oncology, First Affiliated Hospital of Sun Yat - Sen University, Guangzhou, China.
Zebin ChenDepartment of Urology, First Affiliated Hospital of Sun Yat - Sen University, Guangzhou, China.
Jun DongDepartment of Radiation Oncology, First Affiliated Hospital of Sun Yat - Sen University, Guangzhou, China.
Bixiu WenDepartment of Radiation Oncology, First Affiliated Hospital of Sun Yat - Sen University, Guangzhou, China.
Yong FangDepartment of Urology, First Affiliated Hospital of Sun Yat - Sen University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the relationship between the pretreatment body mass index (BMI) and the clinical outcomes in patients with localized stage I - III renal cell carcinoma (RCC) surgically treated. MATERIALS AND

methodsFrom January 2000 to December 2012, 798 patients with stage I - III RCC were recruited from First Affiliated Hospital and Cancer Center of Sun Yat - Sen University. Patients were divided into two groups of BMI < 25 kg / m2 or BMI ≥ 25 kg / m2 according to the World Health Organization classifications for Asian populations. The differences in the long-term survival of these two BMI groups were analyzed.

resultsThe 5 - year failure - free survival rates for BMI < 25 kg / m2 and BMI ≥ 25 kg / m2 groups were 81.3% and 93.3%, respectively (P = 0.002), and the 5 - year overall survival rates were 82.5% and 93.8%, respectively (P = 0.003). BMI was a favored prognostic factor of overall survival and failure - free survival in a Cox regression model.

conclusionsPretreatment body mass index was an independent prognostic factor for Chinese patients surgically treated, localized stage I - III RCC.

Indexed as

Body Mass IndexAdultAgedAged, 80 and overCarcinoma, Renal CellFemaleHumansKidney NeoplasmsMaleMiddle AgedNeoplasm StagingPrognosisRetrospective StudiesSurvival RateBody Mass IndexCarcinoma, Renal CellPrognosis

Identifiers

PMID30516928
PMCPMC6442171

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.